Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Apatinib Mesylate
2. Rivoceranib
3. Rivoceranib Mesylate
4. Yn-968d1
5. Yn968d1
1. 811803-05-1
2. Rivoceranib
3. Apatinib Free Base
4. Yn968d1
5. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide
6. N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
7. 5s371k6132
8. N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide
9. 3-pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-
10. Unii-5s371k6132
11. Apatinib (in China)
12. Rivoceranib [inn]
13. Rivoceranib (usan/inn)
14. Rivoceranib [usan]
15. Rivoceranib [who-dd]
16. Gtpl7648
17. Schembl1814966
18. Chembl3186534
19. Apatinib Free Base; Yn-968d1
20. Dtxsid601024366
21. Amy21302
22. Bcp02840
23. Ex-a1794
24. Hy-13342a
25. Mfcd21648511
26. Nsc772886
27. Nsc799333
28. S5248
29. Zinc70466461
30. Akos024464453
31. Ccg-268625
32. Db14765
33. Ds-7455
34. Nsc-772886
35. Nsc-799333
36. Sb16590
37. N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide
38. Ncgc00249393-01
39. Ncgc00249393-08
40. Ac-27461
41. Ba175030
42. Da-35324
43. Cs-0003200
44. C76598
45. D11288
46. Ab01274807-01
47. Ab01274807_02
48. Q27262801
49. N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide
50. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide
Molecular Weight | 397.5 g/mol |
---|---|
Molecular Formula | C24H23N5O |
XLogP3 | 4.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 397.19026037 g/mol |
Monoisotopic Mass | 397.19026037 g/mol |
Topological Polar Surface Area | 90.7 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 608 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
ABOUT THIS PAGE
40
PharmaCompass offers a list of Rivoceranib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rivoceranib manufacturer or Rivoceranib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rivoceranib manufacturer or Rivoceranib supplier.
PharmaCompass also assists you with knowing the Rivoceranib API Price utilized in the formulation of products. Rivoceranib API Price is not always fixed or binding as the Rivoceranib Price is obtained through a variety of data sources. The Rivoceranib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A apatinib (in China) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of apatinib (in China), including repackagers and relabelers. The FDA regulates apatinib (in China) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. apatinib (in China) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A apatinib (in China) supplier is an individual or a company that provides apatinib (in China) active pharmaceutical ingredient (API) or apatinib (in China) finished formulations upon request. The apatinib (in China) suppliers may include apatinib (in China) API manufacturers, exporters, distributors and traders.
click here to find a list of apatinib (in China) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A apatinib (in China) DMF (Drug Master File) is a document detailing the whole manufacturing process of apatinib (in China) active pharmaceutical ingredient (API) in detail. Different forms of apatinib (in China) DMFs exist exist since differing nations have different regulations, such as apatinib (in China) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A apatinib (in China) DMF submitted to regulatory agencies in the US is known as a USDMF. apatinib (in China) USDMF includes data on apatinib (in China)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The apatinib (in China) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of apatinib (in China) suppliers with USDMF on PharmaCompass.
apatinib (in China) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of apatinib (in China) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right apatinib (in China) GMP manufacturer or apatinib (in China) GMP API supplier for your needs.
A apatinib (in China) CoA (Certificate of Analysis) is a formal document that attests to apatinib (in China)'s compliance with apatinib (in China) specifications and serves as a tool for batch-level quality control.
apatinib (in China) CoA mostly includes findings from lab analyses of a specific batch. For each apatinib (in China) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
apatinib (in China) may be tested according to a variety of international standards, such as European Pharmacopoeia (apatinib (in China) EP), apatinib (in China) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (apatinib (in China) USP).